The FDA and the Next Wave of Drug Abuse — Proactive Pharmacovigilance
Douglas C. Throckmorton(United States Food and Drug Administration), Janet Woodcock(Center for Drug Evaluation and Research), Scott Gottlieb(Schweiger Dermatology Group (United States))
Cited by 73
Related Papers
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
|Clinical Cancer Research|2005|220
PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products
|Kidney International|1995|174
Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony-stimulating factor and interferon gamma.
|The Journal of Experimental Medicine|1995|172